<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783432</url>
  </required_header>
  <id_info>
    <org_study_id>MP432</org_study_id>
    <nct_id>NCT00783432</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis</brief_title>
  <official_title>Active-Controlled Trial of the Safety and Tolerability of a MP03-33 in Patients With Chronic Allergic or Nonallergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine
      hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Adverse Events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Focused Examination of the Head and Neck With Findings Recorded on a Numeric Scale.</measure>
    <time_frame>baseline and 12 months/ET</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adult Mini-Rhinoconjuctivitis Quality of Life Questionnaire. Change From Baseline in RQLQ Score at Months 1,3,6,9 and 12/or Early Termination.</measure>
    <time_frame>baseline, months 1,3,6,9 and 12/or early termination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">862</enrollment>
  <condition>Chronic Allergic Rhinitis</condition>
  <condition>Nonallergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Astepro Nasal Spray (0.1% azelastine hydrochloride)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Astelin Nasal Spray (0.1% azelastine hydrochloride)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Astepro Nasal Spray (0.1% azelastine hydrochloride)</intervention_name>
    <description>548 mcg (2 sprays per nostril) twice a day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Astelin Nasal Spray (0.1% azelastine hydrochloride)</intervention_name>
    <description>548 mcg (2 sprays per nostril) twice a day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients 12 years of age and older with an established history (&gt; 1
             year) of rhinitis due to perennial allergies, non-allergic triggers or vasomotor
             rhinitis (VMR).

          2. Provide written informed consent/pediatric assent. If the patient is a minor, a parent
             or legal guardian must give written informed consent

          3. Willing and able to comply with the study requirements, including daily use of
             medication for a one year period, even if symptoms are not bothersome.

          4. General good health and free of any disease or concomitant treatment that could
             interfere with the interpretation of the study results as determined by the
             investigator or the sponsor's medical officer

          5. Patients receiving immunotherapy (antigen desensitization) must be on a stable
             maintenance regimen for at least 30 days before the first study visit (adjustments to
             regimen following a brief period of missed injections does not preclude participation)

        Exclusion Criteria:

          1. The use of any investigational drug within 30 days prior to screening. No other
             investigational products are permitted for use during the conduct of this study

          2. Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol
             or sucralose (SplendaÂ® brand sweetener)

          3. Women who are pregnant or nursing

          4. Women of childbearing potential who are not abstinent and not practicing a medically
             acceptable method of contraception. Female patients must practice an acceptable
             contraceptive technique for 30 days before randomization and agree to continue its use
             during treatment and for 30 days after the last dose of study drug. Oral,
             intrauterine, implantable, injectable contraceptives, or a double barrier form of
             contraception are acceptable and the medication including dose, device or method must
             have been stable for at least 30 days before the first dose of study drug.

          5. Nasal disease(s) likely to affect deposition of intranasal medication, such as
             sinusitis,rhinitis medicamentosa or clinically significant nasal polyposis or nasal
             structural abnormalities

          6. Patients with asthma (with the exception of mild, intermittent asthma) or other
             significant pulmonary disease such as Chronic Obstructive Pulmonary Disease

          7. Patients with a known history of alcohol or drug abuse

          8. Existence of any surgical or medical condition, which in the opinion of the
             investigator or sponsor, might significantly alter the evaluation of study

          9. Clinically relevant abnormal history and/or physical findings which, in the opinion of
             the investigator or sponsor, would interfere with the objectives of the study or that
             may preclude compliance with the study procedures

         10. Study site staff, immediate relatives of study site staff, or other individuals who
             would have access to the clinical study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lewis M. Fredane, MD</last_name>
    <role>Study Director</role>
    <affiliation>Meda Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meda Clinical Trials Contact Center</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <results_first_submitted>December 29, 2008</results_first_submitted>
  <results_first_submitted_qc>August 27, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 2, 2009</results_first_posted>
  <last_update_submitted>October 1, 2009</last_update_submitted>
  <last_update_submitted_qc>October 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Harry Sacks, MD</name_title>
    <organization>Vice President, Medical and Scientific Affairs</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelastine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First observation 24 July 2006 and last observation 28 Dec 2007</recruitment_details>
      <pre_assignment_details>Subjects participated in a one-week screening period to identify appropriate subjects based on symptom scores</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Astepro Nasal Spray</title>
          <description>(0.1% azelastine hydrochloride)</description>
        </group>
        <group group_id="P2">
          <title>Astelin Nasal Spray</title>
          <description>(0.1% azelastine hydrochloride)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="430">This includes 2 subjects that received a randomization number but did not receive study drug</participants>
                <participants group_id="P2" count="432">This includes 2 subjects that received a randomization number but did not receive study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="345"/>
                <participants group_id="P2" count="354"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>subject moved</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Astepro Nasal Spray</title>
          <description>(0.1% azelastine hydrochloride)</description>
        </group>
        <group group_id="B2">
          <title>Astelin Nasal Spray</title>
          <description>(0.1% azelastine hydrochloride)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="428"/>
            <count group_id="B2" value="430"/>
            <count group_id="B3" value="858"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="389"/>
                    <measurement group_id="B2" value="391"/>
                    <measurement group_id="B3" value="780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.2" spread="14.95"/>
                    <measurement group_id="B2" value="41.3" spread="15.12"/>
                    <measurement group_id="B3" value="41.2" spread="15.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="410"/>
                    <measurement group_id="B2" value="405"/>
                    <measurement group_id="B3" value="815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="388"/>
                    <measurement group_id="B2" value="391"/>
                    <measurement group_id="B3" value="779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Rhinitis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" spread="11.04"/>
                    <measurement group_id="B2" value="11.3" spread="10.85"/>
                    <measurement group_id="B3" value="10.9" spread="10.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Nasal Symptom Score (AM + PM)</title>
          <description>TNSS scale: 0=no symptoms, 1=mild symptoms, 2=moderate symptoms and 3 = severe symptoms scored twice daily such that the maximum daily score is 24.</description>
          <units>units on a scale (0-3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.69" spread="4.506"/>
                    <measurement group_id="B2" value="9.96" spread="4.725"/>
                    <measurement group_id="B3" value="9.82" spread="4.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Adverse Events</title>
        <description>An AE can be any unfavorable and unintended sign,symptom, or disease temporally associated with the use of this investigational product, whether or not considered related to the investigational product. An AE is any untoward medical occurrence in a subject which does not necessarily have a causal relationship with this treatment.</description>
        <time_frame>12 months</time_frame>
        <population>Number of participants for analysis was based on a safety population that included any subject who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Astepro Nasal Spray</title>
            <description>(0.1% azelastine hydrochloride)</description>
          </group>
          <group group_id="O2">
            <title>Astelin Nasal Spray</title>
            <description>(0.1% azelastine hydrochloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Adverse Events</title>
          <description>An AE can be any unfavorable and unintended sign,symptom, or disease temporally associated with the use of this investigational product, whether or not considered related to the investigational product. An AE is any untoward medical occurrence in a subject which does not necessarily have a causal relationship with this treatment.</description>
          <population>Number of participants for analysis was based on a safety population that included any subject who received at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Focused Examination of the Head and Neck With Findings Recorded on a Numeric Scale.</title>
        <description>Examination of head and neck(scale: 0, 1+=Mild, 2+=Moderate, 3++Severe) for mucosal edema, nasal discharge, mucosal erythema, mucosal bleeding, mucosal ulcerations, crusting of mucosa, conjunctiva, tympanic membranes, lymph nodes of head and neck. Direct visual nasal examination (scale: None, Grade 2, Grade 3, and Grade 4) for epistaxis,ulceration and pain.</description>
        <time_frame>baseline and 12 months/ET</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Astepro Nasal Spray</title>
            <description>(0.1% azelastine hydrochloride)</description>
          </group>
          <group group_id="O2">
            <title>Astelin Nasal Spray</title>
            <description>(0.1% azelastine hydrochloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Focused Examination of the Head and Neck With Findings Recorded on a Numeric Scale.</title>
          <description>Examination of head and neck(scale: 0, 1+=Mild, 2+=Moderate, 3++Severe) for mucosal edema, nasal discharge, mucosal erythema, mucosal bleeding, mucosal ulcerations, crusting of mucosa, conjunctiva, tympanic membranes, lymph nodes of head and neck. Direct visual nasal examination (scale: None, Grade 2, Grade 3, and Grade 4) for epistaxis,ulceration and pain.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Conjunctiva: Total baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428"/>
                    <measurement group_id="O2" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctiva: baseline-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264"/>
                    <measurement group_id="O2" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctiva: baseline-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctiva: baseline-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctiva: baseline-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctiva: Total M12/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctiva: M12/ET-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366"/>
                    <measurement group_id="O2" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctiva: M12/ET-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctiva: M12/ET-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctiva:M12/ET-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tympanic membranes: Total baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428"/>
                    <measurement group_id="O2" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tympanic membranes: baseline-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342"/>
                    <measurement group_id="O2" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tympanic membranes: baseline-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tympanic membranes:baselineModerate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tympanic membranes: baseline-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tympanic membranes: Total M12/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tympanic membranes: M12/ET-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405"/>
                    <measurement group_id="O2" value="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tympanic membranes:M12/ET-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tympanic membranes: M12/ET-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tympanic membranes:M12/ET Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphadenopathy: Total baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428"/>
                    <measurement group_id="O2" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphadenopathy: baseline-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389"/>
                    <measurement group_id="O2" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphadenopathy: baseline-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphadenopathy: baseline-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphadenopathy: baseline-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphadenopathy: Total M12/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphadenopathy: M12/ET-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408"/>
                    <measurement group_id="O2" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphadenopathy:M12/ET-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphadenopathy:M12/ET-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphadenopathy: M12/ET-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal edema: Total baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428"/>
                    <measurement group_id="O2" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal edema: baseline-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal edema: baseline-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal edema: baseline-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal edema: baseline-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal edema: Total M12/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal edema:M12/ET-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal edema: M12/ET-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal edema: M12/ET-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal edema: M12/ET-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal discharge: Total baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428"/>
                    <measurement group_id="O2" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal discharge: baseline-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal discharge: baseline-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal discharge: baseline-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal discharge: baseline-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal discharge: Total M12/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal discharge:M12/ET-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal discharge: M12/ET-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal discharge: M12/ET-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal discharge:M12/ET-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal erythema: Total baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428"/>
                    <measurement group_id="O2" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal erythema: baseline-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal erythema: baseline-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal erythema: baseline-Monderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal erythema: baseline-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal erythema: Total M12/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal erythema: M12/ET-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal erythema: M12/ET-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal erythema: M12/ET-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal erythema:M12/ET-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal bleeding: Total baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428"/>
                    <measurement group_id="O2" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal bleeding: baseline-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="362"/>
                    <measurement group_id="O2" value="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal bleeding: baseline-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal bleeding: baseline-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal bleeding: baseline-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal bleeding: Total M12/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal bleeding: M12/ET-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402"/>
                    <measurement group_id="O2" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal bleeding: M12/ET-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal bleeding: M12/ET-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal bleeding: M12/ET-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal ulcerations: Total baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428"/>
                    <measurement group_id="O2" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal ulcerations: baseline-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="348"/>
                    <measurement group_id="O2" value="362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal ulcerations: baseline-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal ulcerations: baseline-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal ulcerations: baseline-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal ulcerations: Total M12/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal ulcerations: M12/ET-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401"/>
                    <measurement group_id="O2" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal ulcerations: M12/ET-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal ulcerations: M12/ET-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal ulcerations: M12/ET-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crusting of mucosa: Total baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428"/>
                    <measurement group_id="O2" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crusting of mucosa: baseline-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293"/>
                    <measurement group_id="O2" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crusting of mucosa: baseline-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crusting of mucosa: baseline-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crusting of mucosa: baseline-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crusting of mucosa: Total M12/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crusting of mucosa: M12/ET-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387"/>
                    <measurement group_id="O2" value="382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crusting of mucosa: M12/ET-Mild (1+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crusting of mucosa: M12/ET-Moderate (2+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crusting of mucosa:M12/ET-Severe (3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis: Total baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428"/>
                    <measurement group_id="O2" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis: baseline None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402"/>
                    <measurement group_id="O2" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis: baseline Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis: baseline Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis: baseline Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis:Total M12/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis: M12/ET None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413"/>
                    <measurement group_id="O2" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis: M12/ETGrade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis:M12/ET Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis: M12/ETGrade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulceration: Total baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428"/>
                    <measurement group_id="O2" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulceration: baseline None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365"/>
                    <measurement group_id="O2" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulceration: baseline Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulceration: baseline Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulceration: baseline Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulceration: Total M12/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulceration:M12/ET None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404"/>
                    <measurement group_id="O2" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulceration: M12/ET Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulceration: M12/ET Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulceration: M12/ET Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Total baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428"/>
                    <measurement group_id="O2" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: baseline None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="377"/>
                    <measurement group_id="O2" value="382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: baseline Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: baseline Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: baseline Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Total M12/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: M12/ET None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401"/>
                    <measurement group_id="O2" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: M12/ET Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: M12/ET Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: M12/ET Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adult Mini-Rhinoconjuctivitis Quality of Life Questionnaire. Change From Baseline in RQLQ Score at Months 1,3,6,9 and 12/or Early Termination.</title>
        <description>The RQLQ consists of 7 domains rated on a 7-point scale with 0 being not troubled by the allergy symptoms,and 6 being extremely troubled. Total possible RQLQ score is 42 at any given evaluation. Scale of how troubled is:0=Not,2=Somewhat,3=Moderate,4=Quite a bit,5=Very,6 Extremely. Only change from baseline to month 12 primary analysis is provided.</description>
        <time_frame>baseline, months 1,3,6,9 and 12/or early termination</time_frame>
        <population>Analysis is based on safety population, which is defined as subjects who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Astepro Nasal Spray</title>
            <description>(0.1% azelastine hydrochloride)</description>
          </group>
          <group group_id="O2">
            <title>Astelin Nasal Spray</title>
            <description>(0.1% azelastine hydrochloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Adult Mini-Rhinoconjuctivitis Quality of Life Questionnaire. Change From Baseline in RQLQ Score at Months 1,3,6,9 and 12/or Early Termination.</title>
          <description>The RQLQ consists of 7 domains rated on a 7-point scale with 0 being not troubled by the allergy symptoms,and 6 being extremely troubled. Total possible RQLQ score is 42 at any given evaluation. Scale of how troubled is:0=Not,2=Somewhat,3=Moderate,4=Quite a bit,5=Very,6 Extremely. Only change from baseline to month 12 primary analysis is provided.</description>
          <population>Analysis is based on safety population, which is defined as subjects who took at least one dose of study medication.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="1.103"/>
                    <measurement group_id="O2" value="2.18" spread="1.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="1.007"/>
                    <measurement group_id="O2" value="-0.83" spread="0.959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="1.063"/>
                    <measurement group_id="O2" value="-1.00" spread="1.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.04" spread="1.206"/>
                    <measurement group_id="O2" value="-0.94" spread="1.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="1.228"/>
                    <measurement group_id="O2" value="-1.16" spread="1.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12/Early termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="1.385"/>
                    <measurement group_id="O2" value="-0.90" spread="1.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size was based on ICH Guideline E1:The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions. Comparisons performed using ANCOVA with baseline as a covariate. The model included treatment group and country as fixed effects to estimate least squares means.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.368</p_value>
            <p_value_desc>This is the Baseline P-Value</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size was based on ICH Guideline E1:The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions. Comparisons performed using ANCOVA with baseline as a covariate. The model included treatment group and country as fixed effects to estimate least squares means.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.327</p_value>
            <p_value_desc>This P-Value if for Month 1</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size was based on ICH Guideline E1:The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions. Comparisons performed using ANCOVA with baseline as a covariate. The model included treatment group and country as fixed effects to estimate least squares means.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.991</p_value>
            <p_value_desc>This P-Value is for Month 3</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size was based on ICH Guideline E1:The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions. Comparisons performed using ANCOVA with baseline as a covariate. The model included treatment group and country as fixed effects to estimate least squares means.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.168</p_value>
            <p_value_desc>This P-Value is for Month 6</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size was based on ICH Guideline E1:The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions. Comparisons performed using ANCOVA with baseline as a covariate. The model included treatment group and country as fixed effects to estimate least squares means.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.319</p_value>
            <p_value_desc>This P-Value is for Month 9</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size was based on ICH Guideline E1:The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions. Comparisons performed using ANCOVA with baseline as a covariate. The model included treatment group and country as fixed effects to estimate least squares means.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.725</p_value>
            <p_value_desc>This P-Value is for Month 12/ET</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Astepro Nasal Spray</title>
          <description>(0.1% azelastine hydrochloride)</description>
        </group>
        <group group_id="E2">
          <title>Astelin Nasal Spray</title>
          <description>(0.1% azelastine hydrochloride)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7"/>
                <counts group_id="E2" subjects_affected="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Battery change for internal cardiac defibrillator</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="430"/>
              </event>
              <event>
                <sub_title>Exacerbation angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="430"/>
              </event>
              <event>
                <sub_title>Central Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="430"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Abdominal Colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="430"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="430"/>
              </event>
              <event>
                <sub_title>Acute Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="430"/>
              </event>
              <event>
                <sub_title>Pneumonia Chlamidalis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="430"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Knee traumatism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="430"/>
              </event>
              <event>
                <sub_title>Fracture left foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="430"/>
              </event>
              <event>
                <sub_title>Broken nose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="430"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exacerbation right shoulder pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="430"/>
              </event>
              <event>
                <sub_title>Total right hip replacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="430"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Rectal Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="430"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="430"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="430"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="430"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Spontaneous Abortion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="430"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Removal of bladder stones</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="430"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="430"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="430"/>
              </event>
              <event>
                <sub_title>Exertional dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="430"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="163"/>
                <counts group_id="E2" subjects_affected="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="428"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="430"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="49" subjects_affected="49" subjects_at_risk="428"/>
                <counts group_id="E2" events="43" subjects_affected="43" subjects_at_risk="430"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="428"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="430"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="428"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="430"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="428"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="430"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For multicenter studies, joint publication is required to assure that the initial publication is based on all data from all sites and investigators participating in these studies agree not to present data gathered individually or by subgroup centers before the initial publication unless jointly agreed by all other investigators and the Sponsor. Authorship will be determined by mutual agreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Wheeler, PhD</name_or_title>
      <organization>Meda Pharmaceuticals</organization>
      <phone>732-564-2351</phone>
      <email>wwheeler@medapharma.us</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

